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Latent infection by members of the gammaherpesvirus family is typically characterized by stable episomal maintenance
of genomic viral DNA. In the case of Epstein–Barr virus (EBV), this is dependent upon binding of the Epstein–Barr nuclear
antigen 1 (EBNA1) to sites which lie within the origin of plasmid replication (OriP). The recently discovered Kaposi’s sarcoma-
associated herpesvirus (KSHV) encodes the latency-associated nuclear antigen (LANA), which appears to be important for
supporting the latent infection of human cells by KSHV. The present work describes site-specific binding of the LANA protein
to multiple different elements at the left end of the genome, a region which appears to be critical for maintenance of KSHV
episomes. Of the three sites, terminal LANA-binding region 4 (TLBR4) binds LANA with the highest affinity when compared
to the other sites. Further characterization of this cis-acting element by mutagenesis studies indicates that the minimal
TLBR4-binding sequence is represented by a 13-bp sequence 59 CGCCCGGGCATGG 39. Furthermore, this specific binding
to TLBR4 was mediated by the distal 200 amino acid C-terminus of the LANA protein. © 2001 Elsevier ScienceINTRODUCTION
The Kaposi’s sarcoma-associated herpesvirus (KSHV)
or human herpesvirus eight (HHV8) is a gammaherpes-
virus that is intimately associated with the development
of at least three neoplastic conditions: Kaposi’s sarcoma
(KS) (Chang et al., 1994; Dupin et al., 1995; Kedes et al.,
1996; Moore, 1995; Schalling et al., 1995), primary effu-
sion lymphoma (PEL) (Cesarman et al., 1995a; Nador et
al., 1996, 1995), and multicentric Castleman’s disease
(MCD) (Dupin et al., 2000; Soulier et al., 1995). Though
the precise role of this human pathogen in the initiation
and maintenance of cell proliferation in these disorders
remains unclear, some general features of KSHV biology
appear to be somewhat similar to that of the related and
more extensively characterized human gammaherpesvi-
rus, Epstein–Barr virus (EBV).
EBV genomes are maintained in latently infected cells
as multicopy circular episomes, from which a restricted
number of viral genes are expressed (Kieff, 1996). One of
these genes, Epstein–Barr nuclear antigen 1 (EBNA1), is
required in-trans for maintenance and stable propaga-
tion of genomic episomes through many rounds of cell
division (Rawlins et al., 1985). This protein, along with the
1.8 kb of EBV DNA known as OriP, represents the basic
viral machinery by which latent EBV episomes are prop-
agated in infected cells (Lupton and Levine, 1985; Yates
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241et al., 1984, 1985). Interestingly, though EBNA1 appears
to be necessary for latent episome replication, it does
not appear to retain any enzymatic activities, such as
helicase or ATPase, that would be consistent with a
direct role in replication (Aiyar and Sugden, 1998; Aiyar et
al., 1998). Indeed, latent EBV episomes have been shown
to be replicated by the cellular DNA polymerase during S
phase (Adams, 1987). Though some controversy exists
regarding the timing and precise activity of this protein,
EBNA1 is thought to exert its effects by direct binding to
specific viral DNA elements, including OriP (Rawlins et
al., 1985; Reisman et al., 1985). Specifically, OriP contains
two sets of sites to which EBNA1 binds with high affinity
(Rawlins et al., 1985; Reisman et al., 1985). The dyad
symmetry (DS) element contains four EBNA1 consensus
sites (TAGCATATGCTA) and is the functional replicator at
which bidirectional replication is initiated (Gahn and
Schildkraut, 1989; Harrison et al., 1994). The family of
repeats (FR) contains 21 repeats of a 30-bp sequence
that contains the EBNA1 consensus site (Gahn and
Schildkraut, 1989; Rawlins et al., 1985). The FR functions
to prevent loss of viral plasmids in actively dividing cells
likely by tethering plasmids via EBNA1 to cellular meta-
phase chromosomes as they segregate during karyoki-
nesis and also serves as an enhancer of replication
(Krysan et al., 1989; Marechal et al., 1999; Simpson et al.,
1996). Interestingly, the N-terminus of the EBNA1 protein
has recently been shown to be responsible for the chro-
mosomal localization of the protein (Hung et al., 2001;
Marechal et al., 1999; Ohno et al., 1977). The presence of
0042-6822/01 $35.00
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to be necessary for the promotion of efficient episomal
replication by EBNA1 (Hung et al., 2001). Furthermore, by
replacing this domain with either HMG-1 or histone H1
(two known chromosome-binding proteins), the resultant
EBNA1 fusion promoted replication with efficiency equiv-
alent to wild-type EBNA1 (Hung et al., 2001). These data
clearly indicate that the chromosomal localization func-
tion of EBNA1 is critical for its function with regard to
episome replication and maintenance.
Though significant differences are beginning to be-
come apparent, such as EBV, KSHV is maintained in
latently infected cells as a circular plasmid, from which a
restricted set of viral genes are transcribed (Cesarman et
al., 1995b; Decker et al., 1996; Renne et al., 1996a,b;
Russo et al., 1996; Zhong et al., 1996). One of these
genes, orf73, encodes the KSHV latency-associated nu-
clear antigen (LANA), which is one of only a few viral
genes expressed in virtually all cells latently infected by
KSHV (Callahan et al., 1999; Kedes et al., 1997b; Kellam et
al., 1997; Rainbow et al., 1997). As such, reactivity to
LANA has served as a sensitive indicator of clinical
infection by KSHV (Gao et al., 1996; Kedes et al., 1997a,
1996). Though LANA bears no strong sequence similarity
to EBNA1, several lines of evidence have suggested that
these two proteins may perform related functions in
latent infection. Similar to EBNA1, LANA is a multifunc-
tional protein that has been shown to play roles in the
regulation of both transcription and episome mainte-
nance (Ballestas et al., 1999; Ballestas and Kaye, 2001;
Cotter and Robertson, 1999; Friborg et al., 1999; Krithivas
et al., 2000; Lim et al., 2000; Schwam et al., 2000). Sep-
arate studies have shown that the LANA protein serves
to tether KSHV-derived plasmids to metaphase chromo-
somes during mitosis and may thereby promote efficient
replication and segregation of episomes (Cotter and
Robertson, 1999). This tethering mechanism appears to
be mediated by LANA binding simultaneously to chro-
mosomal proteins such as histone H1 and specific DNA
sequences located within the viral episome, as specific
transfected viral cosmids were shown to colocalize to
chromosomes with LANA (Cotter and Robertson, 1999).
These cosmids include Z6 and Z2, which are located at
the left and right ends of the viral genome, respectively
(Cotter and Robertson, 1999). As such, each Z6 and Z2
contain multiple copies of the terminal repeat (TR) se-
quence, which may therefore contain cis-acting se-
quences that mediate chromosomal tethering and ge-
nome maintenance (Russo et al., 1996). Furthermore,
LANA has been shown to bind with relatively high affinity
to a restriction fragment from the far left end of the viral
genome that includes a copy of the terminal repeats
(Cotter and Robertson, 1999). Additional recent studies
have localized a LANA DNA-binding site ;20 bp within
the TR and shown that plasmids containing at least onecopy of the TR may persist in LANA-expressing cells for
at least 1 month (Ballestas and Kaye, 2001). These stud-
ies suggest that cis-acting sequences at the left end of
the viral genome mediate maintenance of the episome
through interaction with LANA and have led us to hy-
pothesize that LANA functions in genome maintenance
by binding to these sequences within this far left end
region, resulting in chromosome tethering and perhaps
plasmid stability and replication.
In this study we describe a multifaceted approach to
identifying candidate LANA-binding sequences within
the KSHV genome. A series of several screening ap-
proaches identified eight candidate-binding sequences,
three of which are shown to bind LANA. The relative
affinity of these sites compared by competitive electro-
phoretic mobility shift assay (EMSA) identified a partic-
ular sequence in the TR, which binds with the highest
affinity. This site, further characterized by a series of
truncated and mutagenized EMSA probes, indicated that
a minimal 13-bp sequence was necessary for binding.
Additionally, binding of this sequence by LANA mapped
to the distal 200 amino acid C-terminus of the LANA
protein. These data are consistent with a multifunctional
model of LANA activity in which multiple different func-
tions of LANA may be exerted by binding to distinct sites
within the KSHV genome.
RESULTS
Identification of potential consensus LANA-binding
sites via randomer immunoprecipitation
In an effort to identify potential LANA-binding sites, a
template for PCR amplification was synthesized which
included KpnI and EcoRI restriction sites flanking a ran-
dom 40-bp oligomer (Fig. 1). Sense and antisense prim-
ers, which annealed to the nonrandom KpnI/EcoRI flank-
ing sequences, were used to amplify a large pool of
random 40-bp oligomers. This DNA was purified and
mixed with anti-myc immunoprecipitates from 293 cells
stably transduced with a myc-tagged LANA expression
construct (Fig. 1). After a period of 30 min, the immuno-
precipitates were centrifuged out of the binding reaction
and washed four times in binding buffer. These beads
were then resuspended, heated at 95°C for 10 min, and
then extracted with phenol:chloroform followed by chlo-
roform isoamyl alcohol. Oligomers that had been precip-
itated with the LANA protein were then recovered from
solution by ethanol precipitation. These recovered oli-
gomers were then used as template in a PCR reaction
with the aforementioned primers to enrich the population
for oligomers, which contained potential LANA-binding
sites. These amplified DNAs were then subjected to
binding with immunoprecipitated LANA, recovery, and
enrichment by PCR amplification.
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immunoprecipitation was conducted five consecutive
times so as to generate a highly enriched population
of oligomers which bound to LANA with high affinity,
while reducing the concentration of oligomers which
may have bound nonspecifically or with low affinity.
This highly enriched population of oligomers was then
digested with EcoRI and cloned into pBluescript
for blue/white screening and sequence analysis of
oligomer inserts. DNA from 50 white ampicillin-resis-
tant colonies were isolated and sequenced. Sequenc-
ing of contained inserts revealed striking homology
among samples. Most inserts fell into one of two
categories, each of which was used to generate a
separate consensus sequence for alignment with the
viral genome. Alignment of these sequences with the
viral genome revealed a similarity between one of the
consensus randomers with a sequence located prox-
imally within the viral long unique region (LUR) at
around base pair 125. Closer inspection of this region
indicated that this sequence was central to an approx-
imately 60-bp sequence that retained a dyad symmetry
reminiscent of the EBV DS element. This sequence
was used to design a probe for EMSA analysis, termi-
nal LANA-binding region 5 (TLBR5, Table 1).
The other consensus sequence from the randomer-
binding screen aligned with a sequence located approx-
imately 1700 bp downstream of the left TR/LUR junction.
While not apparently part of a larger DNA structure po-
tentially indicative of function in replication, this se-
quence bore some similarity to a sequence which flanks
the EBV DS and has been suggested to serve in the
promotion of stability of newly replicated episomes












a Repeat elements (R) found positionally in the KSHV genome simila
b Long Unique Regions of the KSHV genome.
c Terminal Repeats of the KSHV genome.design a synthetic probe for EMSA analysis, TLBR6 (Ta-
ble 1).Identification of candidate LANA-binding sites by
alignment
Since early DNA-binding screens with LANA revealed
the strongest binding to a restriction fragment from the
far left end of the genome, including the terminal repeats,
we also carefully inspected this region for sequences
that might represent part of an origin of replication or
other discrete functional elements to which LANA might
bind. Given that origins of replication in many diverse
systems, including latent viruses such as human papil-
lomavirus (HPV), polyomaviruses, and EBV, contain dyad
symmetry elements (Lu et al., 1993; Reisman et al., 1985),
we became interested in sequences that bore some
structural similarities to these elements. Since LANA has
been shown to homodimerize through the C-terminus
(Schwam et al., 2000) and also heterodimerize through
the C-terminal leucine zipper (Lim et al., 2000), we were
also interested in any palindromic or otherwise repeated
sequences as it may be reasonably postulated that func-
tional DNA binding by LANA may involve dimerization
and therefore recruitment of at least two DNA-binding
domains. In an effort to identify this type of cis-acting
element, the Megalign program was employed to align
the left end of the genome, including the TR with both its
own sense and its antisense strands. An alignment of the
sense strand with itself would identify direct repeats,
while alignment of the sense with the antisense would
reveal palindromic elements or other less obvious re-
gions of dyad symmetry. While the sense/sense align-
ment did not reveal any regions of significant repeat
within this region (1TR11600-bp LUR), it should be noted
that g-2-herpesviruses such as KSHV have a relative
large number of TR units (;40). Because of this, any
identified site within the TR sequence would be found at
in This Study
KSHV coordinates Means of identification LANA binding
236–266 (LURb) Megalign analysis N
475–505 (LURb) Megalign analysis N
341–371 (TRc) Megalign analysis Y
603–619 (TRc) Megalign analysis Y
97–157 (LURb) Randomer selection Y
1683–732 (LURb) Randomer selection N
24285–305 (LURb) Genome inspection N
24625–655 (LURb) Genomic inspection N
at known for Herpesvirus saimiri.ABLE 1
Used
aag
r to thleast once in each of the 40 TR units. Interestingly, the
sense/antisense alignment revealed several regions,
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degree of dyad symmetry. Among these was the TLBR5
dyad symmetry-like sequence identified in the randomer-
binding screen. The results of this alignment are shown
in Fig. 2. The diagonal axis represents corresponding
coordinates between the sense and antisense strands
so that intersecting lines represent aligned sequences
between the two strands at similar coordinates along the
double-stranded viral episome. Because of the highly
GC-rich nature of the TR, the degree of alignment in this
region is substantially greater than that observed in the
coding LUR. This alignment revealed four sequences
other than TLBR5 named TLBR1–4 which each displayed
more predominantly some degree of dyad symmetry (Ta-
ble 1). These sequences were hypothesized to be poten-
tial LANA-binding sites and were used to design EMSA
probes to test this hypothesis. Interestingly, each of
these sequences appeared to be relatively unique in that
no particular consensus or motif was identified as being
common among them.
In addition to the TLBR sequences identified at the left
end of the viral genome, we also noted the presence of
FIG. 1. Schematic depicting randomer approach to identifying
a putative LANA DNA-binding sequence (Hensel et al., 1995).
Randomers (40 bp) with nonrandom flanking sequence were bound
to anti-LANA immunoprecipitates from 293 LANA cells. Randomers
that precipitated with LANA were amplified by PCR and subjected to
four more cycles of binding and amplification before cloning and
sequencing.a highly repetitive region located at about 24 kb within
the LUR. This region spans approximately 717 bp be-tween coordinates 24,285 and 24,902 and is apparently
devoid of coding sequence in the otherwise ORF-rich
viral LUR. The region itself consists of 17 copies of a
20-bp repeat followed by 9 copies of a 30-bp repeat.
Since this structure bears some similarity to the EBV FR
sequence of the OriP and was positionally similar to an
HVS element involved in maintenance, we postulated
that these repeats may represent a target for LANA
binding and perhaps the promotion of episomal persis-
tence (Kung and Medveczky, 1996). For these reasons
each of the two repeat sequences was used to design
EMSA probes to test for binding to LANA (Table 1.)
LANA specifically binds to TLBR3, TLBR4, and TLBR5,
but not TLBR1, TLBR2, TLBR6 the repeat sequences
located at coordinates 24 kb within the KSHV genome
To test the identified candidate sequences for binding
to LANA protein, synthetic oligonucleotides for each
probe listed in Table 1 were annealed with their reverse
complement to generate short double-stranded probes
FIG. 2. Megalign analysis reveals the presence of five candidate
LANA-binding sequences located at the far left end of the viral
genome. The graph represents an alignment between the sense and
antisense strands for one copy of the TR as well as the first 1600 bp
of LUR. Alignment between the two strands at corresponding coor-
dinates identifies potentially palindromic sites or those with some
dyad symmetry. The red horizontal line represents corresponding
coordinates. Small blue lines perpendicular to the red axis repre-
sent alignments at the same location along the double-stranded
DNA molecule and were therefore chosen as candidate LANA-
binding sequences.
245LANA CARBOXY-TERMINUS BINDS TO SITE-SPECIFIC SEQUENCESfor use in an EMSA. The LANA protein was translated in
vitro along with control luciferase to test for specific
binding to each of the indicated probes. Five microliters
of LANA or luciferase translation reaction mixture was
mixed with 20,000 cpm of each probe (Table 1) for 15 min
at room temperature prior to electrophoresis in a nonde-
naturing gel and autoradiography. Representative shift
data for TLBR1–5 are shown in Fig. 3. For TLBR3, TLBR4,
and TLBR5, there are shifted complexes detected only
when in vitro translated LANA, but not luciferase, was
added to the probe prior to electrophoresis. No specific
LANA shift was detected for TLBR1, 2, 6, or either of the
repeat sequences shown in Table 1 (Fig. 3 and data not
shown). Each of the LANA-specific shifts detected with
TLBR3, 4, and 5 were competed by the addition of ap-
proximately 100-fold excess of cold probe for competition
(CC), indicating the specific binding of LANA to each
TLBR3, 4, and 5. The same concentration of irrelevant
cold probe did not compete in any case (data not shown).
Interestingly, similar LANA-specific shifts were detected
with TLBR3 and TLBR5, whereas binding of LANA to
TLBR4 resulted in two relatively slower migrating com-
FIG. 3. EMSA analysis of candidate LANA-binding sequences wi
upon the addition of LANA to radiolabeled TLBR3, 4, and 5, but not
translated luciferase control (Lucif.). Each detected LANA complex w
(cold competitor, CC). Note that TLBR3 and TLBR 5 give rise to s
molecular weight doublet.plexes. It should be noted that these gels were run for
over 18 h to resolve the large complexes and the probeswere not resolved along with the specific LANA EMSA
shifts.
LANA binds TLBR4 with greater affinity than TLBR3
or TLBR5
To compare the relative affinities of LANA for the three
identified binding sequences, the ability of each respec-
tive probe to cold compete a specific shift was analyzed.
In this set of experiments 33-, 83-, 165-, 250-, and 500-
fold of each cold probe was used to compete the specific
shifts for each of TLBR3, 4, and 5. As shown in Fig. 3a,
neither TLBR3 nor TLBR5 were nearly as efficient in
specifically competing the LANA/TLBR4 complex as cold
TLBR4 itself (Fig. 4a, compare left and right panels). In
the case of TLBR3, TLBR4 appeared to compete with
equal efficiency, while TLBR5 competed more effi-
ciently than TLBR3 (Fig. 4b). In the case of TLBR5, neither
TLBR3 nor TLBR4 competed as efficiently as TLBR5;
however, TLBR4 competed somewhat better than TLBR3
(Fig. 4c).
To get a quantitative indication of the ability of each of
tro translated LANA. Specifically shifted complexes were detected
or 2. No such complex was detected upon the addition of in vitro
ecifically competed by the addition of 100-fold excess of cold probe
LANA complexes, while TLBR4 gives rise to a characteristic highth in vi
TLBR1
as sp
imilarthese probes to compete with one another for binding,
the band from Fig. 4 was subject to densitometric anal-
246 COTTER, SUBRAMANIAN, AND ROBERTSONysis using the ImageQuant program. By comparing the
intensity of the uncompeted LANA complex with that of
the competed band, a percentage competition can be
calculated for each tested concentration for each com-
petitor. These numbers were then used to plot percent-
age competition (y axis) against the fold excess cold
competitor (x axis). As suspected, Fig. 5a indicates that
neither TLBR3 nor TLBR5 are efficient at competing a
specific TLBR4/LANA shift, suggesting that TLBR4 may
bind with greater affinity than TLBR5 or TLBR3. In the
case of TLBR3, however, TLBR4 is not as efficient as in
competing the TLBR3 shift as TLBR3 or TLBR5. In this
case, TLBR5 appears to compete with as great an effi-
ciency or slightly better than TLBR3 (Fig. 5b). Interest-
ingly, in the case of TLBR5, neither TLBR3 nor TLBR4
ultimately competed with efficiency, approaching that
FIG. 4. Competitive EMSA analysis of TLBR3, TLBR4, and TLBR5 bi
250-, and 500-fold excess) of opposing probes were used to compet
to cold compete itself with the same concentrations of cold probe (le
sequences.observed for TLBR5 (Fig. 5c). Overall, it appeared that
neither TLBR3 nor TLBR5 were capable of completelycompeting a TLBR4/LANA complex; however, the recip-
rocal experiments, although somewhat less clear, did not
show such a distinct modality. In these experiments, it
appeared that TLBR4 could compete either TLBR3 or
TLBR5 with nearly similar efficiency to that observed for
cold TLBR3 and TLBR5, respectively. Surprisingly, TLBR5
competed TLBR3 with greater specificity than TLBR4 and
was as efficient as TLBR3 (Fig. 5b). This data are con-
sistent with the possibility that LANA binding to TLBR3
and TLBR5 similarly represents a different modality of
LANA binding compared to that observed for TLBR4. The
EMSA data shown previously in Fig. 3 are also consis-
tent with this possibility in that the TLBR3 and TLBR5/
LANA complexes migrated similarly, whereas TLBR4/
LANA migrated more slowly and may be representative
of a multimer of LANA bound to TLBR4. As TLBR4 bound
o in vitro translated LANA. Increasing concentrations (33-, 83-, 165-,
of TLBR3, 4, and 5 (right). This was compared to the ability of each
mpare the relative affinity between LANA and the identified bindingnding t
e each
ft), to cowith higher affinity than TLBR3 and TLBR5, we decided to
further characterize the binding of TLBR4.
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In an effort to better characterize the specificity of
LANA for TLBR4 and the constituency of the shifted
complexes, the EMSA analysis of TLBR4 with in vitro
translated LANA was repeated with a nonspecific DNA
control as well as supershift controls. As expected, the
addition of in vitro translated LANA, but not control lucif-
erase (Luc), resulted in the presence of a high molecular
weight complex that migrated as a doublet (Fig. 6). Each
of these bands are competed by the addition of 1003
excess cold TLBR4 (CC), but not by 1003 excess non-
specific cold DNA (NSCC). This data indicate a high
degree of specificity of LANA for the TLBR4 sequence. To
confirm the presence of LANA in the two shifted bands,
a monoclonal anti-myc antibody was added to the bind-
ing reaction prior to the addition of the radiolabeled
probe. Since the in vitro translated LANA protein con-
tains a myc epitope tag, the addition of anti-myc antibody
would be expected to result in the presence of super-
shifted complexes if the shifted bands do indeed reflect
LANA binding to the probe. As shown in Fig. 6, at least
one supershifted complex emerges upon the addition of
the monoclonal antibody, indicating the presence of
LANA in at least the faster migrating complex. It is
possible that the slower band in the doublet is also
supershifted by the antibody; however, this potential
complex comigrates with a band that appears in the
absence of antibody, rendering its precise identity some-
what unclear. Since probe alone plus the anti-myc anti-
body results in neither of the supershifted complexes,
the possibility of the antibody binding the probe indepen-
dent of protein may be excluded. Additionally, since con-
trol IgG did not result in any supershifted complex, the
possibility of supershifted complexes being the result of
nonspecific association of antibody with shifted com-
plexes may also be excluded. These data clearly indicate
that LANA binds TLBR4 in a sequence-specific fashion.
LANA is expressed and localizes to the nucleus in
HEK293 cells
To verify appropriate expression of LANA in 293 cells,
15 mg each of pA3M LANA and pA3M vector alone were
transfected by electroporation into 107 cells. Eighteen
hours later cells were harvested and lysed for immuno-
blot and immunofluorescence analysis. Lysate from one
million cells from each 293 cell sample was fractionated
by SDS–PAGE along with lysates from BJAB uninfected
negative control cells as well as BC-3 cells, which are
latently infected by KSHV and therefore express endog-
enous LANA. Fractionated proteins were transferred to
nitrocellulose membranes and probed with a KS patient
serum reactive to LANA. As shown in the top panel of
Fig. 7a,293 cells transfected with pA3M LANA express a
protein absent in BJAB and vector-transfected cells,which is similar in size to endogenous untagged LANA
from BC-3 cells. To confirm the identity of the band
detected in the 293 pA3M LANA lysate, the blot was
stripped and reprobed with monoclonal anti-myc anti-
body. As shown in the bottom panel of Fig. 7a, the band
reactive to the KS serum is also reactive to anti-myc
antibodies, confirming its identity as the recombinant
myc-tagged LANA expressed from pA3M LANA in trans-
fected 293 cells.
To verify the nuclear localization of the recombinant
LANA expressed in 293 cells, the same cells analyzed
above by immunoblot were subjected to immunofluores-
cence analysis using the same KS patient serum, fol-
lowed by incubation with FITC-conjugated goat anti-hu-
man secondary antibodies. As shown in Fig. 7b, 293
cells transfected with pA3M LANA (top right) and BC-3
(bottom right) display a similar pattern of specific anti-
LANA nuclear fluorescence. Very little background fluo-
rescence was detected in vector-transfected 293 or un-
infected BJAB cells (top and bottom left panels, Fig. 7b).
It was noted that the pattern detected in the 293 cells
was more diffuse and less punctate than that seen in
BC-3 cells. This has been previously noted and attributed
to the absence of viral episomes to form higher order
tethered complexes on the host chromosomes (Ballestas
et al., 1999). These results indicate that our pA3MLANA
construct expressed LANA, which was translocated to
the nucleus, similar to that seen with LANA expressed
from KSHV genome.
Recombinant LANA expressed in 293 cells binds TLBR4
Since previous binding experiments were conducted
with LANA translated in vitro, we became interested in
whether or not LANA expressed in cells bound to TLBR4
in a similar fashion. To this end nuclear extracts from 293
cells transiently transfected with pA3M LANA and con-
trol pA3M vector alone were prepared 18 h after trans-
fection. These extracts were used for an EMSA con-
ducted in the same way as the EMSA shown in Fig. 6
with in vitro translated LANA. Similar to the results ob-
tained with in vitro translated LANA, extracts from 293
cells transfected with the LANA cDNA shifted TLBR4,
whereas no such shift was detected when extracts from
vector-transfected 293 cells were added to the probe
(Fig. 7c). The LANA-specific bands were readily com-
peted by the addition of 100-fold excess cold TLBR4,
indicating that the presence of the complexes depends
specifically upon the TLBR4 sequence (Fig. 7c).
To verify the presence of LANA in the shifted com-
plexes, supershift analysis was conducted with mono-
clonal anti-myc antibody (directed against the C-terminal
myc epitope tag from pA3M LANA) and control mouse
IgG. As shown in Fig. 7c, the addition of anti-myc results
in the appearance of a robust supershifted complex,
248 COTTER, SUBRAMANIAN, AND ROBERTSONwhereas no such supershifted complex was detected
upon addition of the control mouse IgG. These super-
shifted complexes are not the result of a nonspecific
association between antibody and probe, since, as
shown in Fig. 7c, the addition of anti-myc to probe alone
resulted in no shift whatsoever. This confirms that the
shifts detected from 293 LANA cells do in fact contain
LANA, perhaps differentially complexed with other cellu-
lar proteins. Alternatively the three distinct shifted com-
plexes may reflect different higher order LANA com-
plexes or different posttranslational forms of LANA
bound to probe, which may therefore migrate differently
than unmodified LANA.
Endogenous LANA from KSHV-infected BC-3 cells
binds TLBR4 in several distinct complexes
FIG. 5. Quantitative comparison of the binding sites ability to
compete one another. For each concentration of cold competitor pre-
sented in Fig. 4, percentage competition was calculated by dividing
densitometric counts (ImageQuant program) for each competed band
by the uncompeted band intensity. This data were plotted along the y
axis vs the concentration of each cold competitor (x axis). TLBR4
appears to represent the highest affinity binding site identified here (a),
as it relatively efficiently competes both TLBR3 and TLBR5 (b and c,
respectively), while either of these is capable of efficiently competing
TLBR4.To investigate the possibility of endogenous LANA
binding to the TLBR4 sequence, we generated nuclearFIG. 7. LANA is expressed in transiently transfected HEK293 cells. Ten
micrograms of pA3M LANA or pA3M vector were transfected into 293 cells
and subjected to immunoblot (a) and immunofluorescence (b) analysis.
Eighteen hours after transfection, 106 viable cells were harvested from
each sample: BJAB (uninfected control); BC-3 (KSHV-infected PEL cell line);
293 pA3M LANA; and 293 pA3M. Lysates were fractionated on a 6%
SDS–PAGE gel and probed with a KS patient serum reactive to LANA. As
shown in the top panel of (a), bands of similar high molecular weight are
detected in BC-3 and 293 pA3M LANA, but not BJAB or 293 vector cells,
confirming the expression of LANA in 293 cells. This blot was stripped and
reprobed with monoclonal anti-myc directed against the myc epitope tag
encoded by pA3M. The same high molecular weight LANA protein was
also detected by this antibody only in 293 pA3M LANA cells, indicating that
the myc epitope tag on the recombinant LANA molecule is intact. (b)
Similar results as detected by immunofluorescent analysis using the KS
patient serum. This data again confirm the expression of LANA in tran-
siently transfected 293 cells, similar to that seen in KSHV-infected BC-3
cells, which express endogenous LANA from harbored KSHV episomes.
(c) LANA expressed in 293 cells forms complexes on TLBR4. As before,
addition of nuclear extract from 293 cells transfected with a LANA cDNA
to labeled TLBR4 resulted in at least three shifted complexes, not present
upon addition of luciferase control protein (Luc). These complexes are
specifically competed by the addition of excess cold TLBR4 (CC), but not
by a similar excess of an irrelevant probe (nonspecific cold competitor,
NSCC), indicating a sequence specificity of LANA binding for TLBR4.
Additionally, these complexes are shown to contain LANA as the addition
of anti-myc (directed against the myc epitope tag on LANA), but not control
IgG, resulted in a specific supershift of the LANA complexes. These
supershifts are not the result of antibody-binding probe and depend upon
the presence of LANA as probe alone plus anti-myc resulted in no such
are not the result of antibody-binding probe and depend upon the presence of
LANA as probe alone plus anti-LANA resulted in no such complexes.
FIG. 7—Continued
249LANA CARBOXY-TERMINUS BINDS TO SITE-SPECIFIC SEQUENCESextracts from BC-3, a primary effusion lymphoma cell line
that is latently infected by KSHV and therefore expresses
endogenous LANA from resident viral episomes. Control
extracts were made from BJAB cells, a Burkitt’s lym-
phoma cell line that is negative for either KSHV or EBV.
EMSA analysis was conducted similar to that for the
LANA, translated in vitro, and the 293 LANA extracts. As
shown in Fig. 7d, similar results were obtained with the
PEL extracts when compared with that observed for the
293 cells and the LANA translated in vitro. Once again,
several shifted complexes were detected with the in-
fected BC-3 nuclear extracts that were not present upon
addition of control BJAB extract to the TLBR4 probe.
These shifts were also competed with 100-fold excess
FIG. 6. In vitro translated LANA forms two complexes on TLBR4. As
before, addition of in vitro translated LANA to labeled TLBR4 resulted
in two shifted complexes, not present upon addition of luciferase
control protein (Luc). These complexes are specifically competed by
the addition of excess cold TLBR4 (CC), but not by a similar excess of
an irrelevant probe (nonspecific cold competitor, NSCC), indicating a
sequence specificity of LANA binding for TLBR4. Additionally, these
complexes are shown to contain LANA as the addition of anti-myc
(directed against the myc epitope tag on LANA), but not control IgG,
resulted in a specific supershift of the LANA complexes. These super-
shifts are not the result of antibody-binding probe and depend upon the
presence of LANA as probe alone plus anti-myc resulted in no such
complexes.complexes. (d) Endogenous LANA expressed in BC-3 cells forms several
complexes on TLBR4. Similar to results obtained with LANA translated in
vitro and LANA expressed in 293 cells, addition of nuclear extract from
KSHV-infected BC-3 cells to labeled TLBR4 resulted in the formation of
several shifted complexes not present upon addition of luciferase control
protein (Luc). These complexes are specifically competed by the addition
of excess cold TLBR4 (CC), but not by a similar excess of an irrelevant
probe (nonspecific cold competitor, NSCC), indicating a sequence speci-
ficity of LANA binding for TLBR4. Additionally, these complexes are shown
to contain LANA as the addition of rabbit anti-LANA but not control IgG
resulted in a specific supershift of the LANA complexes. These supershiftscold TLBR4 (CC), but not with 100-fold excess of an
irrelevant probe (NSCC). Interestingly, BC-3 extracts gave
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TLBR4, suggesting that perhaps other viral proteins may
be recruited to the LANA-containing complexes on the
TLBR4 sequence. As shown in Fig. 7d, almost all of the
shifts detected with the BC-3 nuclear extracts were su-
pershifted by the addition of a rabbit polyclonal anti-
LANA antibody, whereas none of these complexes were
supershifted by the addition of the control IgG. This
suggests that each of these complexes does contain
LANA and that KSHV-infected cells may establish larger
heteromeric LANA-containing complexes on this se-
quence than extracts that from 293 cells express LANA
as the only viral protein.
Binding to TLBR4 is mediated by the LANA C-terminal
domain
To determine which region of the LANA protein is
responsible for mediating sequence-specific binding to
TLBR4, several truncated LANA constructs were gener-
ated. As shown in Fig. 8a, LANA is a large 1162 amino
acid domain protein with several identified domains. The
N-terminus contains a proline-rich (P-rich) domain, while
the central portion contains a highly repetitive acidic
region, reminiscent of some transcriptional activators.
Although the central repeat is highly acidic, the overall
amino acid sequence varies. The proximal portion of the
repeat, labeled acidic domain (AD), consists primarily of
DEED repeats, while the glutamine rich domain (Q-rich)
comprises primarily DEQQQ repeats. Variation in the
size of this repeat gives rise to some variation in the size
of the LANA protein encoded by different KSHV isolates.
Immediately C-terminal to this acidic region lies a hydro-
phobic heptad repeat region that is presumed to form a
leucine zipper. With the exception of an identified nuclear
localization signal, the LANA C-terminus does not bear
any significant homology to any known protein or domain
structure. Based on this domain architecture, four trun-
cated LANA mutant cDNAs were cloned into a eukary-
otic expression vector. LANA 1–4 consists of amino ac-
ids 1–435 and includes the N-terminal NLS as well as the
proline-rich domain and the first portion of the central
repeat. LANA 1–7 consists of amino acids 1–756 and
includes all the sequences in 1–4 plus the glutamine-rich
repeat region. LANA 1–950 also includes the leucine
zipper and part of the unique C-terminus. LANA 7–11
encodes amino acids 762-1162, which represents the
entire leucine zipper as well as the entire C-terminus.
These constructs were translated in vitro to generate
corresponding LANA polypeptides. These translated
LANA proteins are shown in Fig. 8b compared to lucif-
erase (Luc) control.
To determine which domain mediates DNA binding to
TLBR4, each of these proteins was subjected to EMSA
analysis with the TLBR4 probe. As shown in Fig. 8c, aspecific shift was detected with the LANA 7–11 polypep-
tide, but not with any of the other LANA constructs. This
shifted complex was readily competed with excess cold
TLBR4 (CC), but not with a similar excess of cold irrele-
vant probe (NSCC), indicating sequence specificity of the
LANA 7–11 protein for the TLBR4 sequence. Further-
more, this complex is shown to contain the LANA 7–11
protein as the addition of anti-myc antibodies (directed
against the myc epitope tag of LANA 7–11) resulted in a
specifically supershifted complex seen before. Control
IgG did not give rise to a supershifted complex nor did
anti-myc give rise to any complex in the absence of
LANA 7–11. These data indicate a specific interaction
between the LANA 7–11 polypeptide and the TLBR4 DNA
sequence. Since a LANA polypeptide corresponding to
amino acids 1–950 did not bind TLBR4, the LANA DNA-
binding sequence may be further localized between
amino acids 951 and 1162.
The C-terminal leucine zipper is not required for
LANA binding to TLBR4
Though these data indicate that the C-terminal 212
amino acids are necessary for DNA binding, they do not
exclude the possibility that the leucine zipper is required
in addition to the 951-1162 sequence. To test this possi-
bility, binding of LANA 7–11 was compared to binding of
a bacterially expressed GST fusion protein that corre-
sponds to the last 237 amino acids of LANA (LANA 9–11).
This GST protein contains the identified C-terminal-bind-
ing sequence, but lacks the leucine zipper present in
LANA 7–11. As shown in Fig. 9, LANA 9–11 gave rise to
a similar shift when compared to that observed for LANA
7–11. As before, this shift was competed with excess
cold TLBR4, but not by a similar excess of an irrelevant
probe of similar length (NSCC). Furthermore this com-
plex was supershifted by the addition of rabbit anti-LANA
antibodies but not with control IgG. The supershift was
not as robust as that observed for 7–11; however, this
may be due to relatively poor recognition of the LANA
9–11 protein by the LANA antibody which was raised
against LANA 7–11. These data indicate that binding by
LANA of TLBR4 DNA is not dependent on the leucine
zipper, but is mediated by the C-terminal 212 amino acids
of the LANA protein.
Localization of the minimal LANA-binding sequence
within TLBR4
To identify more precisely the nucleotides critical for
LANA binding to TLBR4, a series of mutated probes were
synthesized (Table 2). A close examination of the TLBR4
sequence reveals the presence of an 8-bp palindrome
(GCCCGGGC, underlined in Table 2) that was postulated
to be important for LANA binding. To test this possibility,
three mutant probes were synthesized. TLBR4 HS1 is
251LANA CARBOXY-TERMINUS BINDS TO SITE-SPECIFIC SEQUENCESFIG. 8. LANA binds TLBR4 through the C-terminal domain. Several truncated LANA cDNA expression plasmids were constructed. As shown in (a),
these include constructs encompassing amino acids 1–435 (1–4), 1–762 (1–7), 1–950 (1–9), and 762-1162 (7–11). These constructs were translated
in vitro as shown in (b) and tested for binding to TLBR4 by EMSA as before. The left panel of (c) shows that only LANA 7–11 gave rise to a specifically
shifted complex upon the addition of labeled TLBR4. In the right, in vitro translated LANA 7–11 is confirmed to bind TLBR4. As before, addition of in
vitro translated LANA 7–11 to labeled TLBR4 resulted in specifically shifted complexes, not present upon addition of luciferase control protein (Luc).
These complexes are specifically competed by the addition of excess cold TLBR4 (CC), but not by a similar excess of an irrelevant probe (nonspecific
cold competitor, NSCC), indicating a sequence specificity of LANA 7–11 binding for TLBR4. Additionally, all but one of these complexes are shown
to contain LANA 7–11 as the addition of anti-myc (directed against the myc epitope tag on LANA 7–11), but not control IgG, resulted in a specific
supershift of the LANA 7–11 complexes. These supershifts are not the result of antibody-binding probe and depend upon the presence of LANA 7–11
as probe alone plus anti-myc resulted in no such complexes.
252 COTTER, SUBRAMANIAN, AND ROBERTSONidentical to TLBR4 except that the first four bases or the
first half-site of the palindrome are transverted from
GCCC to TAAA (bold, Table 2). TLBR4 HS2 has only the
second half-site of the 8-bp palindrome transverted from
GGGC to TTTA (bold, Table 2). TLBR4 PD represents only
the palindrome flanked on either side by one additional
nucleotide.
These probes were subjected to EMSA analysis with
the binding LANA polypeptide, corresponding to the last
400 amino acids (LANA 7–11), translated in vitro. As
shown in Fig. 10 (left panel), none of these probes gave
rise to a specific shift with LANA, as compared to the
luciferase control. This data indicate that each of the two
half-sites of the palindrome are required for binding;
however, the 8-bp palindrome itself is insufficient for
LANA binding. To localize the additional nucleotides re-
quired for binding, two other mutant probes were de-
signed which extended the TLBR4 PD mutant probe
three nucleotides in each of the 59 and 39 directions
FIG. 9. C-terminal binding of LANA to TLBR4 is independent upon
the leucine zipper. The binding of in vitro translated LANA 7–11 was
compared to binding to a purified GST LANA 9–11 protein, which is
deleted for the leucine zipper. As shown in Fig. 8 before, LANA 7–11
bound efficiently to TLBR4. Additionally, GST LANA 9–11 bound in
the same specific fashion was competed by excess TLBR4 (CC), but
not excess irrelevant probe (NSCC), and was supershifted by the
addition of anti-LANA antibodies. This indicates that the LANA C
terminus distal to the leucine zipper mediates DNA binding to
TLBR4. Note that complexes from LANA 7–11 and LANA 9–11 are
similar in size due to the presence of the 26-kDa GST on the
N-terminus of LANA 9–11.(TLBR4 59, TLBR4 39, Table 2). These sequences were
again tested for binding to LANA via EMSA. As shown inFig. 10 (right panel), TLBR4 39, but not TLBR4 59, gave rise
to a LANA-specific shifted complex. Interestingly, this
complex appears to represent relatively high affinity
binding as 100-fold excess TLBR4 39 competed the com-
plex much less efficiently than the same concentration of
cold competitor seen in previous experiments with wild-
type TLBR4. TLBR4 116 is another KSHV sequence lo-
cated at approximately 116 kb in the KSHV LUR that
aligned with the 59 11-bp sequence from TLBR4 located
in the KSHV TR, which includes the 8-bp palindrome
(Table 2). That LANA did not bind TLBR4 116 suggests
that TLBR4 itself repeated in the TR may be the only
high-affinity LANA-binding sequence in the KSHV ge-
nome. However, taken together, these mutagenesis stud-
ies indicate that the 13-bp TLBR4 39 sequence (CGC-
CCGGGCATGG) represents the minimal LANA binding
sequence.
DISCUSSION
In the few years since its identification, several func-
tions have been assigned to the LANA protein. The fact
that LANA is one of the few viral proteins ubiquitously
expressed in cells latently infected by KSHV has sug-
gested that it might exert a function or functions critical
for the maintenance of the latent phenotype. This has
clearly been brought to bear as LANA has now been
implicated in several processes relevant to viral latency.
First, LANA has been shown to be critical for the stable
maintenance of KSHV-derived cosmids (Ballestas et al.,
1999). Additionally, LANA has been shown to tether
KSHV cosmids to host chromosomes during mitosis,
presumably to ensure efficient segregation of newly syn-
thesized viral episomes to newly formed daughter cells
during mitosis (Cotter and Robertson, 1999).
Long-term maintenance of latent episomes however is
not the only aspect of LANA function. Additional data
have suggested that LANA functions as a regulator of
transcription in a variety of settings. Recent work has
TABLE 2






TLBR4 HS1 TCCCTAAAGGGCATGGG N
TLBR4 HS2 TCCCGCCCTTTAATGGG N
TLBR4 PD CGCCCGGGCA N
TLBR4 59 TCCCGCCCGGGCA N
TLBR4 39 CGCCCGGGCATGG Y
TLBR4 116 CGGTCGGTCCCGCCCGGGGCGCGAA N
Note. The underlined sequences represent the 8-bp palindromic
sequence found in TLBR4 and the bold sequences are the changes
made in that sequence.
253LANA CARBOXY-TERMINUS BINDS TO SITE-SPECIFIC SEQUENCESshown that LANA can protect cells from apoptosis by
negatively regulating p53-dependent transcriptional
events through direct interaction with the p53 protein
(Friborg et al., 1999). LANA has also been shown to
interact with pRb and thereby de-repress E2F-dependent
transcriptional events (Radkov et al., 2000). In targeting
these two key tumor suppressor pathways, LANA is also
likely to play a significant role in malignant transforma-
tion of latently infected cells. Consistent with KSHV’s
controversial role as a tumor virus, we have shown that
LANA has the capacity to transactivate the reverse tran-
scriptase subunit of the human telomerase holoenzyme
(Knight et al., 2001). This is important, as a robust debate
exists in the literature regarding KSHV’s ability to trans-
form cells similar to some closely related gammaherpes-
viruses. Since activation of telomerase is thought of as a
critical step in the process of cellular transformation (Kim
FIG. 10. Sequence requirements for LANA binding to TLBR4. To deter
were constructed (Table 2). TLBR4 HS1 is identical to TLBR4 except th
the 59 end of TLBR4 (GCCCGGGC) are transverted from GCCC to TAAA
from GGGC to TTTA. TLBR4 PD represents only the palindrome flanke
same sequence as TLBR4 PD, with an additional three nucleotides on
116 kb in the KSHV LUR that aligned with the 59 sequence from TLBR4
the TLBR4 39 EMSA probe. Other probes gave rise to similar backgrou
well as LANA.et al., 1994), this data lent additional mechanistic support
for the role of KSHV as a human DNA tumor virus.Several other groups have shown that LANA maintains
the capacity to repress transcription in a number of other
settings. One group has shown that LANA interacts with
the mSin3/HDAC1 co-repressor complex to repress tran-
scription (Krithivas et al., 2000). By interacting with a
histone deacetylase, LANA may therefore mediate the
posttranslational modification of histone tails specifically
at promoters to which it is recruited. Another group,
Choe and co-workers have reported that LANA interacts
with and inhibits the ATF4/CREB2 transcription factor
(Lim et al., 2000), which is a key regulator/activator of
transcription and is known to interact with several mem-
bers of the basal transcriptional machinery, such as
TFIIB, and TBP (Liang and Hai, 1997). Wilson and col-
leagues have shown, by a series of GAL4 DBD-LANA
fusion studies, that both the N- and C-terminal domains
of LANA maintain a repressive capacity (Schwam et al.,
e minimal-binding sequence within TLBR4, a series of mutated probes
irst four bases or the first half-site of an 8-bp palindrome located near
HS2 has only the second half-site of the 8-bp palindrome transverted
ther side by one additional nucleotide. TLBR4 59 and 39 represent the
side, respectively. TLBR4 116 is a sequence located at approximately
KSHV TR, including the 8-bp palindrome. LANA bound specifically to






nd ban2000). Another more comprehensive study of LANA’s
effects on promoters containing classical transcription
254 COTTER, SUBRAMANIAN, AND ROBERTSONfactor-binding sites has shown that LANA can activate
promoters containing ATF-, AP-1-, and Sp1-binding se-
quences (Renne et al., 2001). Additionally, LANA has also
been shown to activate transcription from its own pro-
moter (Jeong et al., 2001; Renne et al., 2001). Taken
together, the current evidence supports a multifunctional,
complex role for this 222- to 234-kDa protein in the
promotion of latent infection by KSHV.
The present work is focused on the DNA-binding prop-
erty of LANA. Our previous data indicated that LANA
could bind to several regions within the KSHV genome;
however, at least one relatively high affinity site is lo-
cated at the far left end of the genome, including the TR
and the proximal LUR. Several different sequence-
screening approaches were therefore undertaken which
identified a total of three sequences that are bound by
LANA. The screening of a random oligomer pool for
sequences that bind LANA revealed a candidate se-
quence (TLBR5) that aligns with a dyad symmetry ele-
ment at bp 97–157, which is bound by LANA as shown by
EMSA. The other sequence, identified in the random
oligomer screen, aligned to a region located between bp
1682 and 1732. Though this sequence did not appear to
bind in vitro translated LANA in an EMSA, it is possible
that LANA’s interaction with this sequence is not direct
and depends upon the presence of other cellular or viral
proteins. This possibility is not excluded as the randomer
screen was conducted with recombinant LANA immuno-
precipitated from 293 cells. These immunoprecipitates
likely contain other cellular interacting proteins com-
plexed with LANA, which might modulate LANA’s ability
to bind DNA. Consistent with this possibility, our recent
study of LANA transactivation of the hTERT has shown
that LANA likely acts through a proximal portion of the
promoter, where several Sp1 sites that have been shown
to be important for hTERT expression are resident. Anal-
ysis by EMSA of LANA’s effect on Sp1 binding to these
sites showed that LANA either prevents Sp1’s interaction
with its cognate sites or forms a high molecular weight
complex with Sp1 bound to its cognate sequence, which
was not resolved on a nondenaturing gel (Knight et al.,
2001).
The implementation of the Megalign program identi-
fied a number of candidate LANA-binding sequences.
EMSA analyses revealed that two of these sequences,
TLBR3 and TLBR4, both bind LANA. These sequences
are both located within the TR and are thus repeated at
up to 40 times in a TR-fused circular episome. Both of
these sequences are GC rich and therefore bear some
resemblance to one another; however, neither of them
bear any significant similarity to the aforementioned
TLBR5, located in the proximal LUR. Recently, during
review of this manuscript, TLBR4 was shown indepen-
dently by other groups to bind LANA (Ballestas and Kaye,
2001; Garber et al., 2001). These data therefore suggestthat LANA may retain several modes of DNA binding and
therefore may bind different DNA sequences specifically,
perhaps to exert distinct functions, consistent with its
already documented multifunctional roles. This has been
shown to be the case for LANA’s EBV functional ho-
molog, EBNA1. An electron microscopic examination of
purified EBNA1 binding to viral episomes revealed the
presence of four EBNA1 binding loci in addition to those
located at the DS and FR elements of OriP. These addi-
tional sites bore little sequence homology to well-char-
acterized OriP binding sequence (Reischig et al., 1987).
Additional studies presented here have mapped a
LANA DNA-binding domain to the distal C-terminus, not
including the leucine zipper. While the leucine zipper has
been shown to be important for interaction with other
transcription factors such as ATF4/CREB2 (Lim et al.,
2000), LANA self-association was shown to be mediated
by a sequence downstream of the leucine zipper
(Schwam et al., 2000). This region is overlapping with the
LANA DBD identified here. This data therefore does not
exclude the possibility that LANA requires self-associa-
tion or dimerization to bind DNA. Interestingly, the amino
acid sequence responsible for localizing LANA to chro-
mosomes has been mapped to the very proximal N-
terminus: amino acids 5–22 (Piolot et al., 2001). That
LANA may use opposite poles of its amino sequence to
bind chromosomes and viral DNA is supportive of a
tethering model of LANA function that we previously
proposed (Cotter and Robertson, 1999). This arrange-
ment would potentially allow the least amount of steric
interference for LANA in bridging viral episomes to host
chromosomes by simultaneously interacting with both.
While LANA is herein shown to bind several DNA
sequences, it remains likely that by binding at least one
of these sites LANA promotes maintenance and replica-
tion of latent viral episomes. One or more of these sites
is therefore likely to be part of a KSHV OriP. Interestingly,
another latent DNA tumor virus, HPV, encodes two pro-
teins which are required for replication. The HPV E1 is a
helicase which binds the origin with low-sequence spec-
ificity, but requires interaction with the HPV E2 transcrip-
tional regulator protein to initiate replication (Dixon et al.,
2000; Rocque et al., 2000). Given this precedent, it is
possible that LANA’s interaction with these sites may be
enhanced by the presence of other viral or cellular pro-
teins. The precise means by which LANA may promote
replication through interaction with an origin remains
unclear. One attractive hypothesis involves LANA having
an intrinsic helicase function, which would facilitate the
denaturation of the origin of replication so that the repli-
some may access single-stranded DNA templates and
commence bidirectional replication. This has been
shown to be the case for maintenance origin binding
proteins encoded by other latent DNA viruses including
human papillomavirus , herpes simplex virus (HSV), and
255LANA CARBOXY-TERMINUS BINDS TO SITE-SPECIFIC SEQUENCESpolyoma viruses such as SV40 (Bruckner et al., 1991;
Challberg and Kelly, 1989; Crute et al., 1991; Dixon et al.,
2000; Rocque et al., 2000; Stahl et al., 1986). Interestingly,
the functional homolog in EBV, EBNA1 appears to retain
neither a helicase activity nor any activity intuitively rel-
evant to the initiation of DNA replication (Aiyar et al.,
1998). Careful study of the LANA protein will be neces-
sary to ascertain whether it may function as a helicase or
through an alternate mechanism perhaps similar to the
rather obscure strategy effected by EBNA1.
That the identified binding sites for LANA include a
dyad symmetry element indicates that the latency mech-
anism employed by KSHV may at least in some ways be
similar to that of other known latent viruses. As men-
tioned previously, the OriP of EBV contains a similar dyad
symmetry element, but also a family of repeats less than
2 kb away. It should be noted however that replication of
plasmids containing the DS but lacking the FR has been
observed, albeit at a lower level than that seen in the
presence of the FR (Yates et al., 2000). This indicates that
the FR serves as an enhancer of replication, whereas the
DS serves as the actual origin. An examination of the
KSHV sequence reveals no obvious analogous FR, al-
though a series of 30- and 20-bp repeats can be found
approximately 23 kb downstream from the identified DS
element. This raises the question of whether KSHV has a
FR that may enhance replication through the DS 23 kb
away, perhaps via linking these DNA elements via a
LANA-containing protein complex. EMSA experiments
conducted with DNA from both these 20- and 30-bp
repeat failed to yield any binding to LANA, however.
Another perhaps more likely possibility involves se-
quences from the TR serving a FR-like function; however,
the DS may be sufficient for efficient replication of KSHV
episomes as it appears to be for HPV and other latent
DNA viruses, including EBV.
The particular location of TLBR5 starting at bp 97
suggests that LANA may exert pleiotropic functions even
by binding this one site. That this particular location
includes the ATG codon of the K1 ORF as well as some
of the upstream sequence suggests that LANA may also
play a role in the transcriptional regulation of this largely
lytic cycle gene (Lee et al., 1998a,b). This seems likely
given that LANA has already been shown to specifically
repress transcriptional events. Binding to this specific
element may therefore be a means by which LANA
protein orchestrates not only the maintenance of latency
but also repression of the lytic phenotype. In this way the
LANA protein may couple regulation of transcription and
replication. Careful experimental consideration should
be given to these possibilities as well as the relevance of
similar or different binding sites throughout the viral and
host cellular DNA.MATERIALS AND METHODS
Plasmids
The construction of pA3M LANA is described else-
where (Cotter and Robertson, 1999). pCDNA3 LANA DC
(aa 1–950) and pCDNA3 LANA NDLZ (aa 1–756) were a
generous gift from Dr. Joonhoe Choe, Korea Advanced
Institute of Science and Technology, Taejeon, Korea (Lim
et al., 2000). pA3M LANA 3–9 (aa 301–942) and pA3m
LANA 7–11 (aa 762-1162) were created by ligation of the
appropriate PCR products amplified from pA3M LANA
into pA3M in frame with the myc epitope tag. pGEX LANA
7–11 (aa 762-1162) was constructed by ligation of a
PCR-generated LANA 7–11 cDNA from pA3M LANA into
pGEX 2TK (Pharmacia) in frame with the N-terminal GST
tag. pGL12 was a generous gift from Dr. Diane Hayward,
Johns Hopkins University School of Medicine, Baltimore,
MD. pGL12 represents LANA (aa 940-1177) cloned into
the pGEX-derived pGH413 (Krithivas et al., 2000).
Cell lines
The 293 pA3MLANA and 293 pA3M vector cell lines
have been described previously. The KSHV-infected pri-
mary effusion lymphoma BC-3 cell line was obtained
from ATCC (Arvanitakis et al., 1996). The virus-negative
Burkitt’s lymphoma cell line BJAB was a gift from Dr.
Elliott Kieff, Harvard University, Cambridge, MA. 293 cells
were maintained in Dulbecco’s modified Eagle medium
(Gibco) supplemented with 10% fetal calf serum, penicil-
lin (25 U/ml), streptomycin (25 mg/ml), and gentamicin (10
mg/ml). BJAB and BC-3 cells were maintained in RPMI
1640 (Gibco) supplemented with 10% fetal calf serum
(20% for BC-3), and the same type and concentration of
antibiotics as for 293 cells.
Immunoprecipitation and Western blot analysis
293 pA3M LANA (50 3 106) and 293 pA3M (50 3 106)
vector cells were lysed with RIPA buffer supplemented
with protease inhibitors as previously described (Cotter
and Robertson, 1999). This lysate was precleared with
Protein G–Sepharose to eliminate nonspecific binding,
followed by the addition of 2 ml monoclonal anti-myc
ascites. LANA-myc/anti-myc immune complexes were
precipitated by the addition of 30 ml Protein G–Sepha-
rose followed by centrifugation. Precipitates were
washed several times with RIPA buffer and resuspended
in 100 ml EMSA buffer with protease inhibitors. To verify
the presence of LANA in the immunoprecipitate, 10 ml of
this sample was subjected to SDS–PAGE and transferred
to nitrocellulose for Western blot analysis. The blot was
blocked in 6% milk–PBS followed by a 1:300 dilution of
the monoclonal anti-myc ascites and a 1:2500 dilution of
HRP-conjugated anti-mouse secondary antibodies (Am-
ersham Pharmacia Biotech.). Alternatively, blots were
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(preadsorbed with BJAB extract), followed by a 1:5000
dilution of a Protein A–HRP secondary (Amersham Phar-
macia Biotech.). Standard chemiluminescent procedures
(Amersham Pharmacia Biotech.) were used to detect
bound antibodies upon exposure to autoradiography
film.
Immunofluorescence
BC-3, BJAB, and 293 LANA or 293 cells were spread on
a microscope slide and fixed in acetone/methanol (1:1).
Prior to antibody incubation, cells were blocked with 20%
normal goat serum, followed by three 5 min washes in
13 PBS. Slides were then incubated with a 1:50 dilution
of serum from a KS patient preadsorbed with BJAB anti-
gens for 1 h at room temperature in a humidity chamber.
Slides were washed three times, 5 min in 13 PBS, prior
to incubation with FITC-conjugated goat anti-human sec-
ondary antibodies at a dilution of 1:1000 in 13 PBS.
Slides were again washed four times, 5 min in 13 PBS,
prior to mounting in antifade with a coverslip. Slides
were examined using an Olympus BX60 fluorescence
microscope. Images were captured using Esprit v1.2 im-
age processing software.
Randomer-binding experiments
Oligomers (40 bp) with flanking EcoRI and KpnI restric-
tions were PCR amplified using a synthetic template and
primers as described previously (Hensel et al., 1995).
Amplified randomers were purified after agarose gel
electrophoresis and resuspended in TE buffer at a con-
centration of 1 mg/ml. Binding reactions were conducted
for 30 min at room temperature in 50 ml EMSA buffer with
protease inhibitors. Binding reactions included 10 ml
resuspended LANA/Protein G–Sepharose and 2 mg pu-
rified randomers. After 30 min LANA/randomer com-
plexes were precipitated by centrifugation and washed
four times in 200 ml EMSA buffer. Washed complexes
were resuspended in PBS, heated at 65°C for 20 min,
and extracted with phenol:chloroform and then chloro-
form:isoamyl alcohol before ethanol precipitation to re-
cover LANA-binding randomers. These recovered rando-
mers were resuspended and used as a template in the
aforementioned PCR reaction before again conducting
the binding protocol. This cycle was completed five con-
secutive times before recovered randomers were di-
gested with EcoRI and cloned into pBluescript (Pharma-
cia) for sequence analysis. Fifty white transformants
were harvested; DNA was isolated and sequenced with
a standard T7 sequencing primer and the Thermo Se-
quenase sequencing kit (Amersham Pharmacia Biotech.)
according to manufacturers recommendations.Protein extracts and electrophoretic mobility shift
assay
Probes indicated in Tables 1 and 2 were prepared by
using synthetic oligonucleotides (Invitrogen). Comple-
mentary oligonucleotides were annealed and purified
from a 12% acrylamide gel in 0.53 TBE by standard
protocols. Probes with GATC 59 overhangs were end-
labeled with the Klenow fragment of DNA polymerase I
and [32P]dGTP. Nuclear extracts were prepared by resus-
pending 50 3 106 cells in 500 ml buffer A (10 mM HEPES,
10 mM KCl, 1.5 mM MgCl2, 5 mM DTT, 0.5 mM PMSF, 10
mg/ml Aprotinin), followed by a 1-h incubation on ice and
then 15 strokes in a Dounce homogenizer. Extracted
nuclei were collected by centrifugation and resuspended
in 250 ml buffer B (20 mM HEPES, 10% glycerol, 420 mM
NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 5 mM DTT, 0.5 mM
PMSF, 10 mg/ml Aprotinin). After 30 min on ice, nuclear
debris was removed by centrifugation. The nuclear ex-
tract supernatant was added to an equal volume buffer C
(20 mM HEPES, 30% glycerol, 1.5 mM MgCl2, 0.2 mM
EDTA, 5 mM DTT, 0.5 mM PMSF, 10 mg/ml Aprotinin) and
snap frozen in aliquots for storage at 280°C. LANA
constructs were transcribed and translated in vitro ac-
cording to manufacturer’s recommendations (TNT kit,
Promega). GST fusion proteins were prepared after over-
night induction of protein expression at 30°C in LB me-
dium, supplemented with 0.5 mM isopropyl-B-D-thioga-
lactopyranoside (IPTG). Bacterial cells were harvested
by centrifugation and resuspended in 1.5 ml NETN (20
mM Tris pH 8.0, 0.5% NP-40, 100 mM EDTA, 0.5 mM
PMSF, 10 mg/ml Aprotinin). After 15 min on ice, 900 ml
Sarkosyl in STE (100 mM NaCl, 10 mM Tris pH 7.5, 1 mM
EDTA) and 75 ml 1 M DTT were added prior to sonication.
Cell debris was removed by centrifugation at 10,000 g for
10 min. The supernatant was supplemented with 5%
Triton X-100 and rotated for 4 h at 4°C with 100 ml
glutathione–Sepharose beads (Amersham-Pharmacia
Biotech.). Protein concentration for nuclear extracts and
purified GST fusion proteins was determined by standard
Bradford assay. EMSA-binding reactions were prepared
with either 5 ml protein translated in vitro or approxi-
mately 10 mg nuclear extract, or 1 mg purified GST pro-
tein, mixed with 50 ng dIdC nonspecific competitor and
20,000 cpm probe in 50 ml buffer: 20 mM HEPES pH 7.5,
0.01% NP-40, 5% glycerol, 10 mM MgCl2, 100 mg/ml BSA,
2 mM DTT, 1 mM PMSF, 40 mM KCl. For cold competition
assays, the indicated amount of cold competitor was
added 5 min prior to the radiolabeled probe. For super-
shift assays, monoclonal anti-myc ascites, KS patient
serum, rabbit polyclonal anti-LANA, or control mouse IgG
(Santa Cruz Biotechnology) was added 5 min prior to the
probe. Binding reactions proceeded for 15 min at room
temperature prior to electrophoresis in a 4 or 5% nonde-
naturing polyacrylamide gel in 0.53 TBE. After electro-
257LANA CARBOXY-TERMINUS BINDS TO SITE-SPECIFIC SEQUENCESphoresis, gels were dried and exposed to autoradiogra-
phy film or phosphorimager screens (Molecular Devices)
for quantitative analysis with ImageQuant software.
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